Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
复制标题
DOI：
10.1371/journal.pone.0195575
复制
发表时间：
2018
期刊：
影响因子：
3.7
通讯作者：
End Hep C SF
中科院分区：
文献类型：
--
作者：
Facente SN;Grebe E;Burk K;Morris MD;Murphy EL;Mirzazadeh A;Smith AA;Sanchez MA;Evans JL;Nishimura A;Raymond HF;End Hep C SF
End Hep C SF于2016年启动，是一项旨在消除旧金山弗朗西斯科（HCV）感染的综合举措。引入直接作用的抗病毒药物来治疗和治愈HCV提供了消除的机会。为了正确衡量进展情况，需要估计基线HCV患病率和活动性HCV感染的各种亚群人数，以确定干预措施的目标和衡量干预措施的影响。我们的分析旨在纳入多个相关数据来源，并估计整个旧金山弗朗西斯科人群的HCV负担，包括感染风险较高的特定关键人群。我们的估计是基于2010年至2017年病例登记、医疗记录、观察性研究和已发表文献中发现的数据的三角测量。我们检查了基于性别、年龄和/或HCV风险组的亚群。当多个数据源可用于亚群估计时，我们使用逆方差加权计算加权平均值。可信范围（CR）来自人口规模和患病率估计的95%置信区间。我们估计21，758名旧金山弗朗西斯科居民为HCV血清阳性（CR：10，274 - 42，067），总体血清阳性率为2.5%（CR：1.2%- 4.9%）。其中，16，408人估计为病毒血症（CR：6，505 - 37，407），尽管这一估计包括治疗病例;其中多达12，257人（CR：2，354 - 33，256）未经治疗且具有传染性。去年注射毒品的人占病毒血症型HCV感染的67.9%。我们估计大约有7,400例（51%）HCV血清阳性病例比旧金山弗朗西斯科HCV监测病例登记册中的病例多。我们的估计提供了一个有用的基线，根据该基线可以测量终末期肝炎C SF的影响。
Initiated in 2016, End Hep C SF is a comprehensive initiative to eliminate hepatitis C (HCV) infection in San Francisco. The introduction of direct-acting antivirals to treat and cure HCV provides an opportunity for elimination. To properly measure progress, an estimate of baseline HCV prevalence, and of the number of people in various subpopulations with active HCV infection, is required to target and measure the impact of interventions. Our analysis was designed to incorporate multiple relevant data sources and estimate HCV burden for the San Francisco population as a whole, including specific key populations at higher risk of infection. Our estimates are based on triangulation of data found in case registries, medical records, observational studies, and published literature from 2010 through 2017. We examined subpopulations based on sex, age and/or HCV risk group. When multiple sources of data were available for subpopulation estimates, we calculated a weighted average using inverse variance weighting. Credible ranges (CRs) were derived from 95% confidence intervals of population size and prevalence estimates. We estimate that 21,758 residents of San Francisco are HCV seropositive (CR: 10,274–42,067), representing an overall seroprevalence of 2.5% (CR: 1.2%– 4.9%). Of these, 16,408 are estimated to be viremic (CR: 6,505–37,407), though this estimate includes treated cases; up to 12,257 of these (CR: 2,354–33,256) are people who are untreated and infectious. People who injected drugs in the last year represent 67.9% of viremic HCV infections. We estimated approximately 7,400 (51%) more HCV seropositive cases than are included in San Francisco’s HCV surveillance case registry. Our estimate provides a useful baseline against which the impact of End Hep C SF can be measured.
登录
查看更多内容
DOI：
10.1007/s11524-017-0145-2
发表时间：
2017-06-01
影响因子：
6.6
作者：
Hughes, Alison J.;Chen, Yea-Hung;Raymond, H. Fisher
通讯作者：
Raymond, H. Fisher
影响因子：
4.1
作者：
Martin NK;Vickerman P;Dore GJ;Hickman M
通讯作者：
Hickman M
影响因子：
3.1
作者：
Raymond, H. Fisher;Chu, Priscilla;Pandori, Mark
通讯作者：
Pandori, Mark
影响因子：
11.8
作者：
Ly, Kathleen N.;Hughes, Elizabeth M.;Holmberg, Scott D.
通讯作者：
Holmberg, Scott D.
DOI：
10.15585/mmwr.mm6354a1
发表时间：
2016-10-14
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Adams, Deborah A;Thomas, Kimberly R;Anderson, Willie J
通讯作者：
Anderson, Willie J